{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:20Z","timestamp":1790286920042,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Immune-related adverse events secondary to immune checkpoint inhibitors (ICI) are increasingly recognised. Lipodystrophy is a rare condition which results in the selective loss of adipose tissue. We describe a case of a 48-year-old woman who had been treated with pembrolizumab for lymph node-positive breast cancer. She was referred to the diabetes service for worsening hyperglycemia, hypertriglyceridemia, and rapid onset of weight loss which occurred a year into pembrolizumab therapy. Examination was consistent with a diagnosis of severe lipodystrophy with severe loss of facial and limb adipose tissue. Investigations including a low leptin level and loss of adiposity on whole body composition analysis were consistent with this diagnosis. A trial of pioglitazone was associated with an improvement in insulin resistance and hypertriglyceridemia, although no improvement in her facial lipodystrophy was observed.<\/jats:p>","DOI":"10.3389\/fendo.2025.1710985","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:17:30Z","timestamp":1765862250000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Generalized lipodystrophy following immune-checkpoint inhibitor therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Andrew-Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny E.","family":"Gunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011271","article-title":"Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations","volume":"13","author":"Wu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): A systematic review and delineation from type 1 diabetes","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2019-0234","article-title":"A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic Malignant melanoma","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"luad025","DOI":"10.1210\/jcemcr\/luad025","article-title":"Marked hypoleptinemia precedes overt fat loss in immune checkpoint inhibitor-induced acquired generalized lipodystrophy","volume":"1","author":"Dhanasekaran","year":"2023","journal-title":"JCEM Case Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2022.516","article-title":"Nivolumab associated endocrine abnormalities: challenging cases from a reference clinic","volume":"18","author":"Unal","year":"2022","journal-title":"Acta Endocrinol (Buchar)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: A new cause of anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","article-title":"Acquired lipodystrophy associated with immune checkpoint inhibitors","volume":"30","author":"Gnanendran","year":"2020","journal-title":"Melanoma Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14588","article-title":"Facial lipodystrophy after immunotherapy with Nivolumab","volume":"19","author":"Drexler","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7326\/L19-0635","article-title":"Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade","volume":"172","author":"Eigentler","year":"2020","journal-title":"Ann Intern Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12986-022-00689-x","article-title":"Sex- and body mass index-specific reference intervals for serum leptin: a population based study in China","volume":"19","author":"Cheng","year":"2022","journal-title":"Nutr Metab (Lond)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.146874","article-title":"Assessment of insulin sensitivity\/resistance","volume":"19","author":"Gutch","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Med (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02142","article-title":"Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy","volume":"9","author":"Corvillo","year":"2018","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.05.012","article-title":"Thiazolidinediones regulate adipose lineage dynamics","volume":"14","author":"Tang","year":"2011","journal-title":"Cell Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1710985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:17:31Z","timestamp":1765862251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1710985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":22,"alternative-id":["10.3389\/fendo.2025.1710985"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1710985","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"article-number":"1710985"}}